Henning Hölder
Henning Hölder is a financial analyst known for his insights into stock market trends and company evaluations. He has been recognized for his critical assessments of companies' financial performances and market positions, particularly in the context of the dermatology sector. Recently, he provided commentary on Galderma's stock performance, highlighting concerns regarding investor expectations and the company's valuation amidst fluctuating market conditions.
Not in the pool (under ¢1).
Recent news mentions
Henning Hölder is mentioned in the context of Swiss companies affected by the dollar's weakness.
Welche Schweizer Unternehmen die Dollarschwäche zu spüren bekommen
Switzerland· 2025-07-18
Henning Hölder is mentioned in the context of the analysis of Barry Callebaut's performance.
Kommentar zu SGS, Barry Callebaut, Tecan, R&S und SPSSwitzerland· 2025-07-11
Henning Hölder is mentioned as part of the sign-off in the article.
Mr Market zu Aryzta, Idorsia, Kühne + Nagel, Tecan und DKSHSwitzerland· 2025-05-08
Henning Hölder provides insights on the skepticism surrounding Novartis and its CEO.
Warum die Börse Novartis trotz guter Zahlen nicht belohntSwitzerland· 2025-04-29
Henning Hölder is mentioned as part of the closing remarks in the article.
Börsenkommentar zu Lindt, Logitech, VAT, SGS und Meier ToblerSwitzerland· 2025-04-08
Henning Hölder is mentioned as having made a relevant comment regarding the stock numbers in the third quarter.
Galderma leider unter der eigenen BeliebtheitSwitzerland· 2025-03-06